Odyssey raises more than $300M as biotech goes public in IPO

endpts.com·May 8, 2026

Odyssey Therapeutics has raised over $300 million through its initial public offering (IPO), focusing on the development of drugs for autoimmune diseases.

Odyssey Therapeutics successfully raised $279 million in its IPO, signaling strong investor confidence in biotech companies focused on autoimmune disease drug development. For professionals tracking biotech IPOs, this move highlights potential investment opportunities in companies with a robust pipeline in niche therapeutic areas.

Want more content like this?

twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.

Create Your Own →Explore Newsfeeds

More from Healthtech & Biotech News

Recent stories curated alongside this one.

endpts.com
New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
Novo Nordisk has secured a partnership for its early-stage Parkinson's cell therapy, while also announcing label expansions for two drugs aimed at rare diseases. Additionally, Genmab has discontinued a Phase 1 cancer trial.
endpts.com
Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
Inhibrx, a biotech company based in San Diego, reports that its experimental drug INBRX-106, when combined with Merck's Keytruda, was more effective in shrinking tumors in patients with metastatic head cancer than Keytruda alone.
statnews.com
STAT+: Astellas treatment offers new hope to a devastated rare disease community
The FDA is facing potential leadership changes with questions about Commissioner Marty Makary's future, while there are developments in a revived gene therapy for a rare disease and disappointing adoption rates for Alzheimer's drugs.
fiercebiotech.com
<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>
Inhibrx Biosciences' OX40 agonist combined with Keytruda significantly increased response rates in a midphase clinical trial, prompting the biotech to move forward with the program, which has garnered interest from Merck & Co.
fiercebiotech.com
<a href="https://www.fiercebiotech.com/biotech/enterprise-reports-phase-2-cystic-fibrosis-win-succeeding-where-big-pharma-stumbled" hreflang="en">Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled</a>
Enterprise Therapeutics' cystic fibrosis drug candidate has successfully met its primary endpoint in a phase 2 trial, advancing the company's efforts in a field previously explored by other firms like Vertex.

Browse all Healthtech & Biotech News →

Odyssey raises more than $300M as biotech goes public in IPO

Want more content like this?

More from Healthtech & Biotech News

New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China

Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

STAT+: Astellas treatment offers new hope to a devastated rare disease community

<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&amp;A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>

<a href="https://www.fiercebiotech.com/biotech/enterprise-reports-phase-2-cystic-fibrosis-win-succeeding-where-big-pharma-stumbled" hreflang="en">Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled</a>

<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>